A short course of the interleukin-1 receptor antagonist, anakinra, appeared safe but did not reduce complications of acute myocarditis in the ARAMIS trial.
MoonLake Immunotherapeutics, a developer of an antibody-derived treatment for inflammatory skin conditions, is exploring a sale, according to people familiar with the matter.
There is no difference in the risk of myocardial infarction with interleukin-6 (IL-6) vs anti-tumor necrosis factor (TNF) therapy for rheumatoid arthritis.
People with moderate-to-severe ulcerative colitis benefit from a combination of these monoclonal antibodies, compared with induction with either agent alone, according to a new phase 2a study.